These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39191757)

  • 1. The HOXC10/NOD1/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer.
    Li K; Yang B; Du Y; Ding Y; Shen S; Sun Z; Liu Y; Wang Y; Cao S; Ren W; Wang X; Li M; Zhang Y; Wu J; Zheng W; Yan W; Li L
    Bone Res; 2024 Aug; 12(1):47. PubMed ID: 39191757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers.
    Guerra SL; Maertens O; Kuzmickas R; De Raedt T; Adeyemi RO; Guild CJ; Guillemette S; Redig AJ; Chambers ES; Xu M; Tiv H; Santagata S; Jänne PA; Elledge SJ; Cichowski K
    Cancer Cell; 2020 May; 37(5):705-719.e6. PubMed ID: 32243838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone-metastatic lung adenocarcinoma cells bearing CD74-ROS1 fusion interact with macrophages to promote their dissemination.
    Wang Z; Lei Z; Wang Y; Wang S; Wang JP; Jin E; Liu X; Sun R; Zhang HT
    Oncogene; 2024 Jul; 43(28):2215-2227. PubMed ID: 38802647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 6. Pan-cancer analysis of homeodomain-containing gene C10 and its carcinogenesis in lung adenocarcinoma.
    Tan X; Li Z; Xie H; Chen J; Xiao J; Zhi Y; Mo H; Huang Y; Liu A
    Aging (Albany NY); 2023 Dec; 15(24):15243-15266. PubMed ID: 38154103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RETRACTED: KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem-Like Cells and Promotes Metastasis.
    Yoon C; Till J; Cho SJ; Chang KK; Lin JX; Huang CM; Ryeom S; Yoon SS
    Mol Cancer Res; 2019 Sep; 17(9):1945-1957. PubMed ID: 31217166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS Mutation-Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling.
    Du F; Cao T; Xie H; Li T; Sun L; Liu H; Guo H; Wang X; Liu Q; Kim T; Franklin JL; Graves-Deal R; Han W; Tian Z; Ge M; Nie Y; Fan D; Coffey RJ; Lu Y; Zhao X
    Theranostics; 2020; 10(16):7335-7350. PubMed ID: 32641995
    [No Abstract]   [Full Text] [Related]  

  • 9. Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway.
    Hsu YL; Huang MS; Yang CJ; Hung JY; Wu LY; Kuo PL
    J Biol Chem; 2011 Oct; 286(43):37335-46. PubMed ID: 21885439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.
    Li K; Liu Y; Ding Y; Zhang Z; Feng J; Hu J; Chen J; Lian Z; Chen Y; Hu K; Chen Z; Cai Z; Liu M; Pang X
    J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36377663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
    Wang Z; Yin M; Chu P; Lou M
    Aging (Albany NY); 2019 Sep; 11(17):7187-7196. PubMed ID: 31484165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
    Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
    Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFβ1.
    Sippel TR; Johnson AM; Li HY; Hanson D; Nguyen TT; Bullock BL; Poczobutt JM; Kwak JW; Kleczko EK; Weiser-Evans MC; Nemenoff RA
    Mol Cancer Res; 2019 Aug; 17(8):1748-1758. PubMed ID: 31088909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
    Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
    J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers.
    Lilja J; Kaivola J; Conway JRW; Vuorio J; Parkkola H; Roivas P; Dibus M; Chastney MR; Varila T; Jacquemet G; Peuhu E; Wang E; Pentikäinen U; Martinez D Posada I; Hamidi H; Najumudeen AK; Sansom OJ; Barsukov IL; Abankwa D; Vattulainen I; Salmi M; Ivaska J
    Nat Commun; 2024 Sep; 15(1):8002. PubMed ID: 39266533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.
    Yang Y; Ahn YH; Chen Y; Tan X; Guo L; Gibbons DL; Ungewiss C; Peng DH; Liu X; Lin SH; Thilaganathan N; Wistuba II; Rodriguez-Canales J; McLendon G; Creighton CJ; Kurie JM
    J Clin Invest; 2014 Jun; 124(6):2696-708. PubMed ID: 24762440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
    Peng DH; Kundu ST; Fradette JJ; Diao L; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Mino B; Yang Y; Minelli R; Peoples MD; Bristow CA; Heffernan TP; Carugo A; Wistuba II; Gibbons DL
    Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
    Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
    Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.